Clinical Trial Update: Imatinib Mesylate in Treating Patients With Metastatic Melanoma [Phase 2]

View source ↗

Summary

Phase 2 trial update evaluating imatinib mesylate in metastatic melanoma; completed study.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• Imatinib mesylate (Imatinib)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Melanoma, Skin Neoplasms | Phase 2 | Status: COMPLETED